Antibody therapeutics for Ebola virus disease

Larry Zeitlin*, Kevin J. Whaley, Gene G. Olinger, Michael Jacobs, Robin Gopal, Xiangguo Qiu, Gary P. Kobinger

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

39 Citations (Scopus)


With the unprecedented scale of the 2014-2016 West Africa outbreak, the clinical and scientific community scrambled to identify potential therapeutics for Ebola virus disease (EVD). Passive administration of antibodies has a long successful history for prophylaxis and therapy of a variety of infectious diseases, but the importance of antibodies in EVD has been unclear and is the subject of some debate. Recent studies in non-human primates have renewed interest in the potential of antibodies to impact EVD. Currently ongoing clinical evaluation of polyclonal and monoclonal antibody therapy in EVD patients in West Africa may finally offer a definitive answer to this debate.

Original languageEnglish
Pages (from-to)45-49
Number of pages5
JournalCurrent Opinion in Virology
Publication statusPublished - 1 Apr 2016

Bibliographical note

Funding Information:
This work was supported by Public Health Agency of Canada (PHAC), the United States Defense Threat Reduction Agency ( HDTRA1-13-C-0018 ), the National Institutes of Health ( U19AI109762 ), and the Biomedical Advanced Research and Development Authority ( HHSO100201400009C ). The contents of the manuscript are solely the responsibility of the authors and do not necessarily represent the official views of the funding agencies.

Publisher Copyright:
© 2016 Elsevier B.V. All rights reserved.


Dive into the research topics of 'Antibody therapeutics for Ebola virus disease'. Together they form a unique fingerprint.

Cite this